|Page (1) of 1 - 12/07/17||email article||print page|
(December 07, 2017)
NEW YORK and MELBOURNE, Australia, Dec. 07, 2017 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) has been named by Frost & Sullivan as the 2017 Global Technology Leader in the Cell Therapy Industry.
Frost & Sullivan Analyst and Industry Manager, Transformational Health, Sanjeev Kumar, said: "Mesoblast is an international industry leader due to its cutting edge mesenchymal lineage cell technology platform, deep intellectual property portfolio, late-phase clinical assets, and industrialized manufacturing capabilities."
Mesoblast is a biopharma company specializing in cell therapies. It has used its proprietary technology platform to establish one of the industry’s most clinically advanced and diverse portfolio of cell-based product candidates. It currently has three cell therapy product candidates in Phase 3 clinical trials, in acute Graft versus Host Disease, chronic heart failure, and chronic lower back pain caused by disc degeneration. The Company expects to report primary endpoint results from its Phase 3 trial in pediatric acute Graft versus Host Disease in Q1 2018.
Mesoblast Chief Executive Silviu Itescu welcomed the award, stating: “We are honored to be the first company named by Frost & Sullivan as the Global Technology Leader in the Cell Therapy Industry. This award recognizes the efforts of the whole Mesoblast team and our investors whose support has been instrumental in the development of our innovative cell therapy product candidates.”
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter